image credit: Adobe Stock

Big pharma resisting temptation for biotech M&A spree until prices drop further

May 5, 2022


Plunging valuations may be forcing biotechs to lay off staff and strip back their pipelines, but Big Pharma doesn’t think the price tags on offer are sufficiently tempting to justify a shopping trip quite yet.

Judging by first-quarter earnings calls over the past two weeks, CEOs of many of the world’s pharma giants believe biotech prices still have a way to drop before they became irresistible acquisitions. While M&A as a means to replenish pipelines is very much on the menu for the big players, it sounds like they are resigned to being picky.

Read More on FierceBiotech